Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2026-04-27 Interim / Quarterly Rep…
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Quarterly Activities/Appendix 4C Cash Flow Report 10 pages 297.1KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 28 April 2026 from Cambium Bio Limited, titled 'Quarterly Cashflow Report & Business Update' for the period ending 31 March 2026. It contains detailed financial data including cash flow figures, operating expenses, investing and financing cash flows, and closing cash balance. It also includes a business update with strategic investment details, FDA regulatory engagement, manufacturing progress, and an updated development timeline. The document includes management commentary and outlook, as well as subsequent events and forward-looking statements. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content is consistent with a quarterly financial report containing substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-27 English
FDA Confirms Single Pivotal Trial Pathway for Elate Ocular 4 pages 163.5KB
Regulatory Filings Classification · 85% confidence The document is an ASX Announcement from Cambium Bio regarding an FDA regulatory update on the single pivotal trial pathway for Elate Ocular®. It is neither a full financial report nor an earnings release, nor does it announce changes in management, capital, dividends, or any other specific category. It is a general regulatory announcement to the stock exchange. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-22 English
Change of Directors Interest Notice - ST 2 pages 354.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings by a director, including number of shares held before and after the change, nature of the change, and consideration paid. This is a report of personal share transactions by a company director. The document length is 3623 characters, which is consistent with a detailed director's dealing notice. There is no indication of financial results, management discussion, or other report types. Therefore, this document fits the definition of Director's Dealing (DIRS).
2026-03-23 English
Application for quotation of securities - CMB 6 pages 18.1KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from Cambium Bio Limited regarding the application for quotation of newly issued securities on the ASX. It details the number and type of securities to be quoted, issue price, and issued capital following quotation. This is a regulatory announcement related to capital markets and securities listing, specifically an application for quotation of shares already issued or to be quoted. It is not a financial report, earnings release, or management discussion. It is also not a report publication announcement but a formal regulatory filing related to securities quotation. Therefore, the document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-03-16 English
Cleansing Notice 1 page 131.7KB
Share Issue/Capital Change Classification · 95% confidence The document is a short notice titled 'CLEANSING NOTICE' under Section 708A(5)(e) of the Corporations Act 2001 (Cth). It announces the issuance of ordinary shares without disclosure under Part 6D.2 of the Corporations Act and confirms compliance with relevant provisions. It also mentions that an Appendix 2A has been lodged with ASX regarding the issue. The document is brief (1310 characters) and serves as a regulatory announcement about a share issue rather than a full financial report or detailed capital update. According to the definitions, announcements about new share issues or capital changes fall under 'Share Issue/Capital Change' (SHA). This is not a full report, nor a certification or a proxy statement, so SHA is the best fit with high confidence.
2026-03-16 English
Results of General Meeting 2 pages 73.0KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 16 March 2026 reporting the results of an Extraordinary General Meeting (EGM) of Cambium Bio Limited. It includes detailed voting results for resolutions passed at the meeting, including approval to issue shares. The document references section 251AA(2) of the Corporations Act 2001 and ASX Listing Rule 3.13.2, which pertain to the disclosure of voting results. The content is focused on the official results of shareholder votes at a general meeting, not the meeting materials or the meeting itself. The document length is under 5,000 characters and it is a formal announcement of voting outcomes rather than a full report or presentation. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-15 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.